Six Readouts in Eight Days: What the Clinical Data Actually Said
Six readouts landed between Oct 19 and Oct 26. Disc and Roche met their trials. EyePoint missed and cut staff. AbbVie, Novartis and Corcept reported the rest.
Two Approvals In, Three Still Waiting: The Back Half of October's FDA Calendar
Roche's Enspryng and Viatris/Opus Genetics' Ryzumvi are approved. GSK, Sun Pharma and INOVIO still await FDA decisions, with goal dates from Oct 26 to Oct 30.
For informational purposes only. Not investment advice, and not an offer or solicitation. Nothing here is a recommendation to buy, sell, or hold any security, and we do not publish price targets. Figures are dated and sourced; they change. Read our full disclaimer.